Influenza A virus vaccine H5N1 - GlaxoSmithKline

Drug Profile

Influenza A virus vaccine H5N1 - GlaxoSmithKline

Alternative Names: (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Dresden) - GSK; (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Adjupanrix; GSK 2590066A; GSK 2592984A; GSK1119711A; GSK1557484A; GSK1562902A; H5N1 (pre-)pandemic influenza virus vaccine - GlaxoSmithKline; H5N1 Clade 1 strain (pre-)pandemic influenza vaccine - GlaxoSmithKline; Pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Pre-pandemic influenza vaccine - GlaxoSmithkline; Prepandrix; Pumarix; Q-Pan H5N1; Split virion, inactivated, adjuvanted (pre-)pandemic H5N1 influenza vaccine - GlaxoSmithKline

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 01 Jul 2016 Phase-II clinical trials in Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Taiwan, Thailand (IM) (NCT02719743)
  • 21 Mar 2016 GlaxoSmithKline plans a phase II trial for Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Thailand, Taiwan and Poland (NCT02719743)
  • 20 Mar 2015 THe vaccine is approved in Europe, and is in phase-III development in Thailand, Taiwan, Singapore and the Philippines and in phase-II development in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top